Wockhardt witnessed a rise in share price on Wednesday after the company announced that abbreviated new drug application (ANDA) of piperacillin and tazobactam for Injection USP, 40.5 g/vial, pharmacy bulk package submitted by Wockhardt Bio AG, subsidiary of the company has been approved by US Food and Drug Administration (USFDA).

Wockhardt's Abbreviated New Drug Application (ANDA) was determined to be therapeutically equivalent to the reference listed drug (RLD) Zosyn for Injection 40.5g/vial, pharmacy bulk package of Wyeth Pharmaceuticals Inc.

Shares of Wockhardt are trading at Rs 735.35, up Rs 7.75, or 1.07% at the Bombay Stock Exchange (BSE) on Wednesday at 10:41 a.m.

The scrip has touched an intra-day high of Rs 746.00 and low of Rs 730.50. The total volume of shares traded at the BSE is 5,539,747.

Total volume of shares traded on the bourses today was higher by 188.36% to 6,233,988 compared with 22-day average volume of 2,161,903.